Loading...
Indication – Lung Cancer2024-06-04T09:56:46+01:00

Lung cancer

Refining treatment approaches in early-stage lung cancer

October 8th, 2024|

At WCLC 2024, Cascone et al. reported preliminary efficacy and safety data for several novel perioperative combinations in patients with stage IIA-IIIB resectable non–small-cell lung cancer (NSCLC) included in Arms 1, 2 and 4 of the open-label, phase II NeoCOAST-2 platform study [1].

Innovative treatment approaches: non–EGFR-directed bispecific antibodies and ADCs

October 4th, 2024|

In the management of patients with advanced PD-L1–positive non–small-cell lung cancer (NSCLC), the use of bispecific antibodies is gaining ground. Ivonescimab (AK112) is a first-in-class bispecific antibody directed against PD-1 and the vascular endothelial growth factor (VEGF) type A. As VEGF and PD-(L)1 inhibitors were found to have synergistic activity, it was postulated that their simultaneous use might enhance treatment efficacy compared with the co-administration of separate anti–PD-(L)1 and anti-VEGF agents [1-3].

HER2 aberrations and other oncogenic drivers

September 30th, 2024|

HER2 mutations are rare as they occur in approximately 2–4 % of NSCLC cases, although they are associated with poor prognosis and increased incidence of brain metastases [1, 2]. As HER2-mutant NSCLC is relatively insensitive to chemo­therapy, there is a substantial unmet need for targeted options [3, 4].

Concurrent MET/EGFR inhibition and third-generation EGFR TKIs

September 30th, 2024|

The EGFR-MET bispecific antibody amivantamab in addition to the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib has shown favorable results as first-line treatment compared to osimertinib in the ongoing randomized, double-blind, phase III MARIPOSA trial. A total of 1,074 patients from 27 countries with advanced non–small-cell lung cancer (NSCLC) and activating EGFR mutations were enrolled in the study.

Preface – WCLC 2024

September 30th, 2024|

It is our pleasure to present highlights from the 2024 World Conference on Lung Cancer, held from September 7th to 10th in San Diego, USA. Our first chapter focuses on the evolving landscape of concurrent MET/EGFR inhibition and novel third-generation EGFR tyrosine kinase inhibitors (TKIs).

Small-cell lung cancer: insights and new treatment options centering around DLL3

October 24th, 2023|

The cell surface protein delta-like-ligand 3 (DLL3) is an emerging therapeutic target in neuroendocrine tumors and neuroendocrine carcinomas such as small-cell lung cancer (SCLC). Approximately 75 % of SCLCs express DLL3. Data reported at ESMO 2023 showed that high DLL3 expression is associated with poor overall survival, advanced pathological grade, and a distinct immune landscape across neuroendocrine neoplasms found in the lung, prostate, and bladder.

Immunotherapy combinations in advanced-stage disease

October 24th, 2023|

As is known, immune checkpoint inhibition plays only a limited role after failure of EGFR- or ALK-targeted treatment in patients with advanced NSCLC; this applies to both monotherapy and combinations with chemotherapy as demonstrated by the CheckMate 722 and KEYNOTE-789 trials.

EGFR-mutated NSCLC: practice-changing results and other notable findings

October 24th, 2023|

In the setting of EGFR-mutated NSCLC, the third-generation EGFR TKI osimer­tinib is the current first-line standard of care, although eventual progression is virtually inevitable. Secondary EGFR and MET alterations have been found to account for 25 % to 50 % of cases of resistance.

Go to Top